PMID: 3768090Sep 1, 1986Paper

Effect of low-dose sitostanol on serum cholesterol in patients with hypercholesterolemia

Atherosclerosis
T HeinemannK von Bergmann

Abstract

Sitostanol (24-ethyl-5 alpha-cholestan-3 beta-ol), a hydrogenated derivative of sitosterol, was administered in a low dose (1.5 g/day) for 4 weeks to 6 patients with hypercholesterolemia. Total cholesterol was reduced significantly after 3 and 4 weeks by 10 and 15%, respectively. The reduction of total cholesterol was entirely due to a fall in LDL cholesterol. Total triglycerides and HDL cholesterol were not altered. Two weeks after cessation of sitostanol administration serum cholesterol returned to pretreatment levels. No significant amounts of sitostanol could be detected in plasma during therapy. These results suggest that low-dose sitostanol might be a useful hypolipidemic agent for the treatment of mild hypercholesterolemia.

References

Sep 3, 1976·Deutsche medizinische Wochenschrift·P OsterH Schmidt-Gayk
May 1, 1970·The Journal of Clinical Investigation·G SalenS M Grundy
Aug 1, 1969·Metabolism: Clinical and Experimental·R G GouldC B Taylor
Dec 1, 1955·Transactions of the New York Academy of Sciences·R G GOULD

❮ Previous
Next ❯

Citations

Dec 21, 2000·Current Atherosclerosis Reports·P J Jones
Aug 9, 2011·Applied Biochemistry and Biotechnology·Xinxin PanTianwei Tan
Mar 26, 2011·Genes & Nutrition·Maria C IzarFrancisco A Fonseca
Nov 1, 1988·Clinica Chimica Acta; International Journal of Clinical Chemistry·H Gylling, T A Miettinen
Jul 5, 2005·The American Journal of Cardiology·Gilbert R Thompson, Scott M Grundy
Jan 5, 2002·Journal of Chromatography. a·A Kuksis
Aug 1, 1987·Baillière's Clinical Endocrinology and Metabolism·R Fears
May 29, 2002·The Journal of Nutritional Biochemistry·C A. VanstoneP J.H. Jones
Nov 16, 1995·The New England Journal of Medicine·T A MiettinenE Vartiainen
Oct 7, 2000·Journal of the American College of Nutrition·T A WilsonR J Nicolosi
Dec 30, 1998·Current Opinion in Lipidology·I Ikeda, M Sugano
Mar 30, 1999·Current Opinion in Lipidology·T A Miettinen, H Gylling
Dec 1, 1993·European Journal of Clinical Investigation·T HeinemannK von Bergmann
Apr 9, 2004·Lipids in Health and Disease·Alvin BergerSuhad S Abumweis
May 11, 2004·Chemical & Pharmaceutical Bulletin·Yang-Heon SongMichung Yoon
Oct 25, 2002·Drugs·Thomas Sudhop, Klaus von Bergmann
May 13, 2014·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·Jordi MerinoFernando Civeira
Apr 29, 2014·Lipids in Health and Disease·Maarit HallikainenHelena Gylling
Feb 1, 2000·The Journal of Cardiovascular Nursing·M WinstonJ Ashley
Apr 25, 2000·Metabolism: Clinical and Experimental·H RelasT A Miettinen
Dec 4, 2014·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·G AssmannC Vetrani
Jun 1, 1997·Annals of Medicine·D Lütjohann, K von Bergmann
Dec 18, 2001·Journal of Pharmaceutical Sciences·K M WasanP H Pritchard

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.